According to Cleveland Clinic och Medscape 1 of the 10 top Medical Innovations

Drugs for Heart Failure With Preserved Ejection Fraction

There currently are no drug therapies specifically indicated for treatment of heart failure

with preserved ejection fraction (HFpEF). Management is directed at accompanying conditions and symptom relief.

However, sodium glucose cotransporter 2 (SGLT2) inhibitors, used for type 2 diabetes, are now being explored for HFpEF in several ongoing trials. Interest in SGLT2 inhibitors for HF was fueled by the observation that they reduced the risk for cardiovascular death and heart failure hospitalization in a cohort of patients with type 2 diabetes.

SGLT2 inhibitors showed similar results in nondiabetic individuals with heart failure and reduced ejection fraction. With an FDA decision anticipated in 2020, these drugs, among others, are introducing potential new treatment options for patients with this heart failure subtype, the Cleveland Clinic noted.



www red DiabetologNytt